• All sections
  • C - Chemistrymetallurgy
  • C07D - Heterocyclic compounds
  • C07D 237/10 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Patent holdings for IPC class C07D 237/10

Total number of patents in this class: 31

10-year publication summary

1
2
1
2
3
1
5
2
0
1
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

Principal owners for this class

Owner
All patents
This class
Abbvie Inc.
1793
3
Tenax Therapeutics, Inc
18
2
Calico Life Sciences LLC
86
2
Ligand UK Development Limited
31
2
Chengdu Hyperway Pharmaceuticals Co., Ltd.
13
2
Glaxo Group Limited
4218
1
Syngenta Participations AG
2715
1
Monsanto Technology LLC
8062
1
Commissariat à l'énergie atomique et aux energies alternatives
10729
1
Korea Institute of Science and Technology
2083
1
Eurofarma Laboratorios S.A.
35
1
Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
119
1
Serum Institute of India Private Limited
102
1
Sloan-Kettering Institute for Cancer Research
481
1
Teikoku Hormone Mfg. Co., Ltd.
1
1
Universidade Federal do Rio de Janeiro-ufrj
83
1
Xcovery Holdings, Inc.
22
1
Alterity Therapeutics Limited
8
1
Kyowa Kirin Co., Ltd.
321
1
Jnana Therapeutics, Inc.
26
1
Other owners 5